Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Get the detailed quarterly/annual income statement for Recursion Pharmaceuticals, Inc. (RXRX). Find out the revenue, expenses and profit or loss over the last fiscal year.
With a single click, unlock detailed, AI-assisted insights pulled from hundreds of financial data points instantly. This price reflects trading activity during the overnight session on the Blue Ocean ...
The desktop application provides the best experience with zero environment setup required. Simply download and run.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback